Refractory Lymphoplasmacytic Lymphoma

Known as: Refractory Lymphoplasmacytoid Lymphoma/Immunocytoma 
Lymphoplasmacytic lymphoma resistant to treatment.
National Institutes of Health

Topic mentions per year

Topic mentions per year

2005-2018
01220052018

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2012
2012
A 64-year-old man with a 2-week history of fatigue and fever presented to the medical admissions unit. He had a background of… (More)
Is this relevant?
Highly Cited
2010
Highly Cited
2010
PURPOSE The phosphatidylinositol 3-kinase/mammalian target of rapamycin (mTOR) signal transduction pathway controls cell… (More)
Is this relevant?
2010
2010
PURPOSE This study aimed to determine activity and safety of weekly bortezomib and rituximab in patients with relapsed/refractory… (More)
Is this relevant?
2010
2010
BACKGROUND Waldenström's macroglobulinemia (WM) is a rare, low-grade lymphoproliferative disorder. Based on preclinical studies… (More)
  • table 1
  • table 1
  • figure 1
  • figure 2
  • table 2
Is this relevant?
2009
2009
8535 Background: This phase II study aimed to determine safety and activity of weekly bortezomib in combination with rituximab in… (More)
Is this relevant?
Highly Cited
2007
Highly Cited
2007
PURPOSE Waldenstrom's macroglobulinemia (WM) is a B-cell disorder. Despite advances in the therapy, WM remains incurable. As such… (More)
  • table 1
  • figure 1
  • figure 2
  • table 2
Is this relevant?
2005
2005
Oblimersen sodium is an antisense oligonucleotide to the first 6 codons of the B-cell leukemia gene 2 (bcl-2) open reading frame… (More)
Is this relevant?